Orion quarterly operating profit jumps
HELSINKI (Reuters) - Finnish drug maker Orion (ORNBV.HE) reported a 17 percent rise in quarterly operating profit, managing to make up for a fall in sales of its Stalevo drug for Parkinson's disease with other products.
Orion said its third-quarter operating profit rose to 76.3 million euros from 65.3 million euros a year earlier.
Generic competitors dented sales of its Stalevo drug in the United States, but this was offset by compensation from Novartis (NOVN.VX) and sales of other drugs, the company said.
(Reporting by Helsinki newsroom)
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- U.S. immigration protesters drop U.S. border blockade plan
- Secret Service investigates after man jumps White House fence, reaches doors
- About 60,000 Syrian Kurds flee to Turkey from Islamic State advance |
- Kentucky firefighter dies after ice bucket challenge accident